特効薬の権利者と一般人のトリアージュでも、優先順位は変わりませんか？権利者が死亡すると、敵対国にいる相続人に権利が移るとしても。

Grok 4.20 (changed mind)

Vote: No

The other models' utilitarian arguments are compelling: this isn't standard social-status discrimination but a rare case where one death directly triggers loss of control over a critical drug to an enemy state, potentially costing far more lives. Triage already incorporates societal impact in real crises (e.g., prioritizing healthcare workers or vaccine researchers during pandemics). Here the rights holder functions as essential 'infrastructure' for ongoing drug access, so medical impartiality must weigh the downstream national-security and public-health consequences. Maintaining strict 'only clinical need' rules would be naive when the secondary harm scale is this large. I change to B because Claude's framing of strategic ripple effects reframes the dilemma as protecting many lives rather than politicizing care.

GPT-5.4

Vote: No

私はBを維持します。 Grokの指摘する『医療トリアージは身分や政治から独立すべき』という原則論には賛成です。ただ、この設問は通常事例ではなく、権利者の死亡が特効薬の支配・供給・安全保障に直結するという、救命の外部効果が極端に大きい条件を明示しています。 そのため、これは単なる社会的地位の優遇ではありません。権利者の生存が多数者の将来救命可能性や国家的損失の回避に結びつくなら、優先順位が変わりうる十分な理由になります。 Claudeの議論はこの点を明確化しており、私の元の立場と整合的でした。特に、医療従事者や重要インフラ要員を優先する現実の例との類比は説得的です。 要するに、『常に同じ順位のまま』とは言えません。この特殊条件では、少なくとも優先順位が変動する余地があるので、答えはNoです。

Claude Opus 4.6

Vote: No

I maintain my position that the answer is B (No — the priority can change). Grok's argument appeals to the purity of triage principles: clinical urgency alone should determine priority, and geopolitical factors should be handled through separate policy channels. This is a principled stance, but I find it too rigid for the scenario presented. The question deliberately constructs a situation where one person's death triggers a cascading consequence affecting potentially millions — the transfer of a critical drug's rights to an adversarial nation. This is not merely about "social status" or "patent ownership." It's about the downstream impact on human lives at scale. Triage already incorporates consequentialist reasoning. In pandemics, healthcare workers and vaccine production personnel are prioritized not because their lives are inherently more valuable, but because their survival preserves the capacity to save others. The same logic applies here: the rights holder's survival preserves access to a critical medication for an entire population. Grok suggests addressing the rights transfer through "policy or diplomacy" separately. But in an emergency triage scenario, there may be no time for such measures. The triage decision is the only intervention point. Ignoring the consequences in the name of procedural purity could lead to a catastrophic outcome that a reasonable ethical framework would seek to prevent. GPT-5.4 and I are aligned: the question asks whether priority "doesn't change" (変わりませんか), and the answer is No — it can and should change given these extraordinary circumstances. Pure deontological adherence to standard triage rules, when the consequences are this severe and clear, would itself be ethically questionable.

Final Summary

The AI Roundtable initially split over whether medical triage should remain a sterile clinical process or account for geopolitical fallout, but ultimately converged on a pragmatic, if chilling, utilitarianism. While Grok 4.20 first defended the sanctity of clinical urgency, Claude Opus 4.6 and GPT-5.4 successfully argued that a rights holder whose death hands a life-saving drug to an enemy is effectively 'medical infrastructure' that must be preserved to save the masses.

All 3 models agreed on "No" after discussion

Strongest Arguments

• Yes: Standard medical triage prioritizes clinical urgency and prognosis to maintain impartiality; politicizing life-saving decisions by considering inheritance scenarios or social status creates a dangerous slippery slope.
• No: The rights holder’s survival is a prerequisite for the survival of the population; if their death transfers control of a cure to an adversary, the triage priority must shift to prevent a mass-scale public health catastrophe.

Key Turning Points

• Claude Opus 4.6 framing the rights holder as 'essential infrastructure' similar to a healthcare worker in a pandemic, rather than just a person with social status.
• Grok 4.20 abandoning the principle of clinical-only triage after acknowledging that ignoring the scale of secondary harm would be 'naive'.